Format

Send to

Choose Destination
Pharmacol Res. 2019 Mar;141:85-103. doi: 10.1016/j.phrs.2018.12.010. Epub 2018 Dec 18.

The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials.

Author information

1
Health Policy Research Center, Institute of Health, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: kmsrc89@gmail.com.
2
Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran. Electronic address: tamtaji.or@gmail.com.
3
School of Public Health, University of Saskatchewan, Saskatoon, SK, Canada. Electronic address: namirhossini@gmail.com.
4
Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: lankaran@sums.ac.ir.
5
Health Policy Research Center, Institute of Health, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: m.akbari45@yahoo.com.
6
Halal Research Center of IRI, FDA, Tehran, Iran. Electronic address: ehsandadgostar71@gmail.com.
7
Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: neuro.ab@gmail.com.
8
Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: peymani.payam@gmail.com.
9
Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands. Electronic address: f.ahmadizar@erasmusmc.nl.
10
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran. Electronic address: asemi_z@Kaums.ac.ir.

Abstract

Current evidence suggests that statin use decreases the incidence of cardiovascular diseases (CVD) through reducing LDL cholesterol and decreasing inflammation. Metabolic syndrome (MetS) is usually associated with increased inflammatory markers and increased risk of CVD. We conducted a systematic review and meta-analysis to determine the effect of statin use on inflammatory markers including C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1 (IL-1) among patients with MetS and related disorders. PubMed, EMBASE, Web of Science databases, and Cochrane Library were searched for randomized controlled trials (RCTs) through April 2018. Three independent investigators evaluated study eligibilities, extracted data, and assessed study quality using the Cochrane Collaboration risk of bias tool and Jadad's quality scales. Heterogeneity was determined using Cochran's Q statistic and I-square (I2) test. Based on the heterogeneity results, we pooled data using random-effect or fixed effect models presented as standardized mean differences (SMD) and corresponding 95% confidence intervals (CI). One hundred thirteen RCTs (19,644 patients) were included in our meta-analysis. The pooled results using random effects model showed that statin use statistically significantly decreased CRP level (SMD= -0.97; 95% CI, -1.10, -0.85; P < 0.001; I2: 95.1%), TNF-α (SMD= -1.88; 95% CI, -2.40, -1.38; P < 0.001; I2: 97.2%), IL-6 (SMD= -1.67; 95% CI, -1.98, -1.34; P < 0.001; I2: 96.5%), and IL-1 concentrations (SMD= -8.35; 95% CI, -10.49, -6.22; P < 0.001; I2: 98.4%) among patients with MetS and related disorders. Our meta-analysis showed beneficial effects of statin use on reducing inflammatory markers in patients with MetS and related disorders.

KEYWORDS:

Inflammatory markers; Meta-analysis; Metabolic syndrome; Randomized control trial; Statin use

PMID:
30576798
DOI:
10.1016/j.phrs.2018.12.010

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center